BioMedNewsBreaks Archive - Page 197 of 215

TuesdayOct 27, 2020 12:30 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries…

TuesdayOct 27, 2020 11:49 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is partnering with the Dalmore Group, a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”), for a regulation A+ offering. Based in New York, the Dalmore Group has an active presence in the Reg A+ equity funding space and is one of the most active broker-dealers in the world for Regulation A+ offerings; the company has served as broker-dealer on more than 50 such offerings in the past year. Brain Scientific recently unveiled its exclusive NeuroCap(TM) device, a next-generation, 19-channel, hospital-grade disposable…

MondayOct 26, 2020 12:52 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion is a result of the company’s achievement of key manufacturing milestones to support upcoming clinical trials of its lead drug candidate — GPX-001 (quaratusugene ozeplasmid). “The appointment of Eric to our senior team is a hallmark of our manufacturing achievements and highlights the progress we have made in scaling up our manufacturing to commercial scale, which will further supply our upcoming clinical trials,” said Michael…

MondayOct 26, 2020 11:49 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Seeking Alpha Article Discussing Its Disruption in Chronic Disease Market

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, was featured in a recent Seeking Alpha news article. The piece, titled “DarioHealth: Don't Overlook This Mini Livongo,” discusses disruptors in the chronic disease market, such as Omada Health, Virta Health and Lark Health. The article specifically focuses on DRIO and the competition it brings to larger players like Livongo Health Inc. (NASDAQ: LVGO), which generated great returns for investors. The article reads, “After LVGO got bought out, I started to look for other digital health plays, specifically competitors to LVGO. Recently, I found a tiny company called DarioHealth (NASDAQ:…

FridayOct 23, 2020 12:06 pm

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

KBL Merger Corp. (NASDAQ, KBLMKBL, KBLMR, KBLMW) (“KBL”), a special purpose acquisition company (“SPAC”) that previously announced the agreement to acquire 180 Life Sciences Corp., today announced postponement of the special meeting of its stockholders (the “Special Meeting”) to November 5, 2020. KBL determined to postpone the Special Meeting (originally scheduled for Monday, October 26, 2020) so that it better aligns with anticipated timing of the proposed business combination with 180 Life Sciences. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL…

WednesdayOct 21, 2020 11:47 am

BioMedNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and…

WednesdayOct 21, 2020 10:53 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstan is vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he…

TuesdayOct 20, 2020 10:06 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. ("Pii"), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for…

MondayOct 19, 2020 12:21 pm

BioMedNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1…

FridayOct 16, 2020 12:45 pm

BioMedNewsBreaks – KBL Merger Corp. IV (NASDAQ: KBLM) Featured in Seeking Alpha Article Discussing ‘Blockbuster Year for SPACs’

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously announced the acquisition of 180 Life Sciences, was featured in a Seeking Alpha news article. The piece discussed a “blockbuster year for SPACs,” indicating that, to date, fiscal year 2020 has seen 127 SPAC IPOs collectively raise over $48.5 billion in proceeds. This represents significantly more than the previous ten years combined. The article covers the process of going public via a SPAC as a cost-effective way to complete a M&A deal in weeks instead…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Seeking Alpha Article Discussing Its Disruption in Chronic Disease Market

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

BioMedNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

BioMedNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

BioMedNewsBreaks – KBL Merger Corp. IV (NASDAQ: KBLM) Featured in Seeking Alpha Article Discussing ‘Blockbuster Year for SPACs’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search